Resorption of small particles and proteins through the mucous membranes of the intestines has been extensively studied for well over a 100 years and the arrival of sublingual/oral immunotherapy in clinical practice has renewed interest in this process. The first line of immune response to a potential allergen is at the site of contact with a mucous membrane and both inhaled and ingested allergens usually lead to some level of direct clinically appreciable manifestation on the mucous membrane. The initial process of antigen resorption has been relatively well understood for almost one century; however, the metabolic and/or immunological fate of large particles is the subject of more recent studies. We now recognize that resorption and hematogenous spread of biologically intact allergens from the gastrointestinal tract occur despite extensive predigestion of particles and proteins within the gastrointestinal lumen and this phenomenon provides the pathophysiological underpinning of modern sublingual/oral immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000071552 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Subcutaneous, Sublingual and Oral Immunotherapy for Allergens: A Comparative Study.
Immunology
January 2025
Department of Allergology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland.
The purpose of this study was to compare the efficacy and safety of subcutaneous, sublingual, oral specific immunotherapy in patients who suffer from allergic conditions to pollen from trees, grasses and weeds, house dust mites and Alternaria alternata spores. A literature search was performed separately for each type of allergen and each administration route of the drug. As a result, it was found that all administration routes were quite effective.
View Article and Find Full Text PDFLong-term IgE immunological tolerance to peanut allergens: An alternative to Noon's daily desensitization paradigm.
Cell Immunol
November 2022
Division of Vaccinology and Immunotherapy, IGE Therapeutics Inc., 10225 Barnes Canyon Road, Suite A106, San Diego, CA 92121, United States.
Article Synopsis
- - Researchers found that sublingual vaccination with peanut allergens created long-lasting IgE immunological tolerance in mice, leading to sustained unresponsiveness for up to 9 months.
- - This method involved using compounds like chenodeoxycholic acid (CDCA) and oleoylethanolamine (OEA) to modify immune responses, resulting in a significant reduction of peanut-specific IgE without affecting IgG levels.
- - The study suggests that this vaccination approach may be more effective than traditional desensitization programs, as it promotes immune tolerance at the dendritic cell level rather than just at the mast cell level.
Peanut oral immunotherapy: current trends in clinical trials.
Immunother Adv
January 2022
Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Immunotherapy for allergy has been practiced for over 100 years. Low-dose repeated exposure to specific allergen extracts over several months to years can successfully induce clinical tolerance in patients with allergy to insect venoms, pollen, house dust mite, and domestic animals. Different regimens and routes for immunotherapy include subcutaneous, sublingual, oral, and intralymphatic.
View Article and Find Full Text PDFDelivery of allergen powder for safe and effective epicutaneous immunotherapy.
J Allergy Clin Immunol
February 2020
Wellman Center for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School. Electronic address:
Background: More effective and safer immunotherapies to manage peanut allergy are in great demand despite extensive investigation of sublingual/oral immunotherapy and epicutaneous immunotherapy (EPIT) currently in the clinics.
Objective: We sought to develop a powder-laden, dissolvable microneedle array (PLD-MNA) for epidermal delivery of powdered allergens and to evaluate the efficacy of this novel EPIT in peanut-sensitized mice.
Methods: PLD-MNA was packaged with a mixture of powdered peanut allergen (PNA), 1,25-dihydroxyvitamin D (VD3), and CpG.
Specific oral immunotherapy in food allergic patients: transient or persistent tolerance?
Postepy Dermatol Alergol
August 2018
Allergy Department, Catholic University, Policlinico A. Gemelli, Rome, Italy.
Introduction: The first therapeutic choice for food allergy is avoidance of the responsible food, but when this approach is not possible, specific oral desensitization could be considered as a good alternative. It is not clear yet whether the acquired tolerance is transient or persistent.
Aim: We report on a subset of 13 patients of a larger study, treated successfully with specific oral tolerance induction who experienced secondary loss of tolerance after a period of allergen avoidance.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!